

A<sup>2</sup>  
CONT'D

0044919.03399  
66660.6162460

4. (Amended) A recombinant MVA according to Claim 1 [claims 1 to 3], wherein said one or more [the] DNA sequences are inserted at the site of one or more naturally occurring deletions within the MVA genome.
5. (Amended) A recombinant MVA according to Claim 1 [claims 1 to 4], wherein said one or more [the] DNA sequences encoding antigen is/are under transcriptional control of the vaccinia virus early/late promoter P7.5.
6. (Amended) A vaccine comprising [containing] at least one recombinant MVA according to Claim 1 [claims 1 to 5] and a pharmaceutically acceptable carrier or diluent.
7. (Amended) A vaccine according to Claim 6 comprising [claim 6 containing] a recombinant MVA comprising DNA sequences encoding a dengue virus type 1 antigen<sub>1</sub>; [a recombinant MVA encoding] a dengue virus type 2 antigen<sub>2</sub>; [a recombinant MVA encoding] a dengue virus type 3 antigen<sub>3</sub>, and [a recombinant MVA encoding] a dengue virus type 4 antigen<sub>4</sub>; [,] and a pharmaceutically acceptable carrier or diluent.
8. (Amended) A method for the treatment or prevention of dengue virus infection comprising administering to a living animal body [, including a human, in need thereof] a therapeutically effective amount of a recombinant MVA according to Claim 1 [claims 1 to 5, or a vaccine according to claims 6 to 7].
9. (Amended) A vaccine comprising first and second components, wherein [as a]  
  
    said first component is a recombinant MVA comprising [carrying] and capable of expressing a DNA sequence encoding T7 RNA polymerase and [as further components]

A1  
conced.

said second component is one or more recombinant DNA vectors each comprising a DNA sequence encoding [carrying] at least one dengue virus antigen under transcriptional control of a T7 RNA polymerase promoter.

10. (Amended) A method for the treatment or prevention of a dengue virus infection comprising inoculating a living animal body [, including a human, in need thereof] with the first and second [further] components of the [a] vaccine according to Claim 9 [claim 9] either simultaneously or with a timelag but using the same inoculation site.

Add the following claims.

11. The method for the treatment or prevention of dengue virus infection of Claim 8, wherein the animal is a human.
12. A method for the treatment or prevention of dengue virus infection comprising administering to a living animal body a therapeutically effective amount of a vaccine according to Claim 6.
13. The method for the treatment or prevention of dengue virus infection of Claim 12, wherein the animal is a human.
14. The method for the treatment or prevention of dengue virus infection of Claim 10, wherein the animal is a human.